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Abstract: Adiponectin is one of the most bioactive substances secreted by adipose tissue 
and is involved in the protection against metabolic syndrome, artherosclerosis and type II 
diabetes.  Research  into  the  use  of  adiponectin  as  a  promising  drug  for  metabolic 
syndromes requires production of this hormone in high quantities considering its molecular 
isoforms. The objective of this study is to produce recombinant human adiponectin by 
Pichia  pastoris  (P-ADP)  as  a  cheap  and  convenient  eukaryotic  expression  system  for 
potential  application  in  pharmaceutical  therapy.  For  comparison,  adiponectin  was  also 
expressed  using  the  Escherichia  coli  (E-ADP)  expression  system.  Adiponectin  was 
constructed by overlap-extension PCR, and cloned in standard cloning vector and hosts. 
Recombinant expression vectors were cloned in the P. pastoris and E. coli host strains, 
respectively. SDS-PAGE and western blotting were used to detect and analyse expressed 
recombinant protein in both systems. Adiponectin was purified by affinity chromatography 
and quantified using the Bradford Assay. The results of this study indicated that P-ADP 
quantity (0.111 mg/mL) was  higher than that of E-ADP  (0.04 mg/mL) and both  were 
produced in soluble form. However, P-ADP was able to form high molecular weights of 
adiponectin molecules, whilst E-ADP was not able to form isoforms higher than trimer. In 
addition, P-ADP was more active in lowering blood glucose compared with E-ADP. The 
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two types of proteins were equally efficient and significantly decreased blood triglyceride 
and increased high density lipoprotein. We conclude that P. pastoris is able to produce 
high quantity of bioactive adiponectin for potential use in treatment of metabolic syndromes. 
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1. Introduction   
Adipose  tissue  has  been  shown  to  play  an  important  role  in  the  regulation  of  body  energy 
homeostasis and metabolism, lipid storage and as an endocrine organ. One of the most important 
factors secreted by adipose tissue is  adiponectin (ADP) [1]. There is  obvious correlation between 
plasma  ADP  levels  and  metabolic  syndrome  [2–4]  and  various  studies  have  shown  a  noticeable 
decrease in ADP levels in patients with obesity, type II diabetes and with the accumulation
 of visceral 
adipose tissue [5–7]. In recent years, ADP has attracted much consideration as a novel therapeutic tool 
for diabetes and metabolic syndromes.   
It is generally accepted that the choice of heterologous protein expression system has profound 
influence  on  characteristics  of  the  recombinant  protein  [8].  Compared  to  prokaryotic  expression 
systems  like  Escherichia  coli,  the  advantages  of  eukaryotic  expression  system  such  as  the 
methylotrophic yeast Pichia pastoris are many. These advantages include an efficient recombinant 
protein  secretion  pathway  for  ease  of  purification,  the  availability  of  eukaryotic  post-translational 
modifications,  fast  growth  on  economic  salt-based  media  and  little  risk  of  contamination  with   
endo-toxins or oncogenic or viral DNAs [9]. Exclusively, P. pastoris has a very low maintenance 
energy
 demand, which  makes  it well suited for high cell density fermentation.  The availability of 
strong and tightly regulated
 promoters makes this yeast a very attractive host for recombinant
 protein 
production [10].   
Different groups have reported expression of different versions of human ADP in various types of 
host. The globular domain of ADP have been successfully expressed in E. coli and P. Pastoris [11,12] 
whilst  the full-length  protein have been expressed in  E. coli  and in  baculovirus based  expression 
systems  [13].  Each  reported  varying  degree  of  success  in  terms  of  yield  and  functionality  of  the 
recombinant  protein.  However,  the  expression  of  recombinant  adiponectin  in  P.  pastoris  and 
evaluation of its activity have not been fully investigated. Therefore, in this study we examined the 
activity of recombinant adiponectin which was produced by P. pastoris (P-ADP) compared with that 
produced by E. coli (E-ADP). The results of this study showed that P-ADP underwent post translation 
modification and has better bioactivity than E-ADP. In addition, P. pastoris expression system was 
efficient in producing high quantity and quality of biologically active recombinant ADP compared 
with E. coli expression system. 
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2. Results   
2.1. Construction and Cloning of Human ADP in P. pastoris and E. coli 
The  results  of  the  overlap-extension  PCR  showed  that  the  full-length  ADP  (735  bp)  was 
successfully obtained using this procedure. The full length ADP encoded variable, collagenous and 
globular
 domains of ADP (Figure 1). Cloning of ADP downstream of the signal peptide and MBP 
sequences was successful in producing MBP-E-ADP periplasm fusion protein. Similarly, cloning of 
ADP in pPICZαA vector after the α-factor signal peptide was successful in producing 6×  His tagged   
P-ADP that would eventually be secreted extracellularly. 
Figure  1.  In  vitro  construction  of  ADP  fragment  using  overlap-extension  PCR.  ADP 
fragment was amplified by PCR through 32 cycles include denaturing step (95 °C  for 45 s), 
annealing step (60 °C  for 45 s) and elongation step (72 °C  for 1 min). The two fragments 
were  then  purified  and  joined  through  10  cycles  of  overlap-extension  PCR  include 
denaturing step at 95 °C  for 45 s, annealing step at 60 °C  for 45 s and elongating step at 
72 °C  for 1 min. L1: PCR product of exon 2 (204 bp). L2: PCR product of exon 3 (531 bp). 
L3: the full length of ADP fragment (734 bp). M: 100 bp DNA marker. 
 
2.1. Expression of ADP in E. coli and Protein Purification   
ADP was inserted downstream of the mal E of E. coli that encodes the maltose binding protein 
(MBP) resulting in the expression of an MBP fusion protein. As such, the amylose resin column 
system was used for purification of this fusion protein. SDS-PAGE results indicated that the expected 
size of the fusion protein was approximately 75 kDa (Figure 2). As mentioned previously, MBP was 
linked to adiponectin protein by four amino acids (ile-glu-gly-arg). This link can be recognized by 
Factor Xa for cleavage and separation of adiponectin from MBP. The expected size of adiponectin 
after digestion with Factor Xa was approximately 30 kDa (Figure 3).   Int. J. Mol. Sci. 2012, 13                         
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Figure 2. SDS-PAGE analysis of adiponectin expression before and after induction with 
IPTG. The expected size of fusion protein (MBP-adionectin) was approximately 75 kDa 
and this can be seen in reference to the protein marker (M). The band of fusion protein was 
faint before induction (L1). However, after induction with IPTG, the fusion protein was 
more detectable (arrow) after 2 h (L2) and 3 h (L3). 
 
 
It is shown that there was no clear difference between protein samples after digestion with Factor 
Xa for different time points. In the positive control that contains crude protein digested with Factor Xa, 
the estimated molecular weight of MBP was higher than that of the adiponectin protein and this protein, 
like other  E. coli native proteins,  was  totally  removed after second purification by amylose resin 
column  (Figure  3).  The  second  purification  was  carried  out  to  eliminate  MBP  residues.  This 
purification was performed by passing the fusion protein cleavage product through the hydroxyapatite 
column to remove maltose residues. The eluted protein was then loaded into the amylose resin column 
and the flow through factions were collected. Protein in the flow through was free of MBP protein and 
consists of adiponectin protein with a total amount of 0.04 mg/mL (Figure 3).   Int. J. Mol. Sci. 2012, 13                         
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Figure 3. SDS-PAGE for optimization of Factor Xa digestion. This figure showed that 
there  was  no  clear  difference  between  protein  digestion  with  Factor  Xa  for  2  h  (L1),   
4 h (L2) and 8 h (L3). Digestion of crude protein with Factor Xa showed that the expected 
size for maltose binding protein (MBP) is approximately 45 kDa whereas the expected size 
of adiponectin protein is approximately 30 kDa (L4). 
 
2.3. Expression of ADP in Pichia pastoris and Protein Yield Optimization   
A time course study was performed to determine optimal methanol induction times, maximum yeast 
growth rate and the best time for protein harvesting (Table 1). SDS-PAGE results showed that the 
expression of adiponectin protein was detected from 12 h after the beginning of methanol induction 
until the 96th hour of induction (Figure 4). Western blot analysis corroborated PAGE results with the 
estimated recombinant protein size of approximately 30 kDa (Figure 5). The highest concentration of 
expressed  P-ADP  protein  was  0.11  mg/mL  obtained  at 60 h  after  the  start  of  methanol  induction   
(Table 1). P-ADP with 6×  His tag was subsequently purified by one step affinity chromatography 
nickel column.   
Figure 4. SDS-PAGE of time-course expression shows the exponential increase in band 
(arrow) densities starting from 12 h to 60 h of P-ADP expression after methanol induction.   
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Figure  5.  P-ADP  molecules  were  detected  by  western  blot  analysis  for  time  course 
expression using adiponectin monoclonal antibody.   
 
Table  1.  The  differences  in  the  optical  density  reading,  total  cells  mass  and  protein 
concentration after methanol induction. 
Hours after methanol 
Induction 
Culture density 
(OD600) 
Total cells mass (g) 
Protein concentration 
(µg/mL) 
12  27.75  1.02  5 
24  36.57  1.49  22 
36  35.5  1.51  25 
48  52.8  1.60  93 
60  49.25  1.60  111 
72  51.33  1.80  78 
86  49.0  1.62  48 
96  43.15  1.78  77 
   
2.4. Analysis of Recombinant Adiponectin Protein Produced by E.coli and P.pastoris 
SDS-PAGE under non-reducing condition was performed to detect the oligomerization process in 
adiponectin protein using anti-adiponectin anti-body. The expected size of the adiponectin monomer 
was approximately 30 kDa for each of the two types of protein. However, the recombinant adiponectin 
protein produced by E. coli showed less oligomers compared with adiponectin protein types that can 
be produced by P. pastoris (Figure 6).   
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Figure 6. SDS-PAGE without denaturing condition showed less oligomers for adiponectin 
protein produced by E. coli compared with that produced by Pichia pastoris. M: Protein 
marker  L1:  Recombinant  adiponectin  produced  by  Pichia  pastoris.  L2:  Recombinant 
adiponectin produced by E. coli. 
 
2.4. Comparison of Biological Activity Between P-ADP and E-ADP 
Comparison  of  biological  activity  between  P-ADP  and  E-ADP  showed  that  both  types  of 
recombinant protein significantly lowered blood glucose throughout the experiment period (Figure 7). 
Additionally, it was also observed that both types of proteins have significant effects on blood lipids 
by  decreasing  triglyceride  levels  and  increasing  HDL  levels  at  the  end  of  the  experiment  period. 
However,  both  these  proteins  showed  no  significant  effect  on  total  cholesterol  and  LDL  levels   
(Figure 8). It is also important to note that P-ADP was significantly more active in lowering blood 
glucose comparing with E-ADP on the experiments conducted above. 
Figure 7. P-ADP and E-ADP significantly lowered blood glucose (t-test, p < 0.01) and there 
was significant difference (t-test, p < 0.05) between P-ADP and E-ADP in lowering blood 
glucose. Data were calculated by mean ±  SEM. 
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Figure 8. Effect of P-ADP and E-ADP on lipid profile after four hours from the first 
injection. The two types of protein significantly (t-test, p < 0.01) lowered the triglyceride 
levels, whereas these proteins caused significant increase (t-test, p < 0.05) in HDL levels. 
There were no significant effects on total cholestrol levels or LDL levels . Also, there were 
no significant differences between P-ADP and E-ADP. Data were calculated by mean ±  SEM. 
 
3. Discussion 
It has been shown previously that adiponectin functions as regulators of insulin sensitivity, glucose 
homeostasis and lipid metabolism [14–16]. The failure of adiponectin monomers to assemble into 
trimers  would  result  in  impaired  secretion  from  the  cell,  and  subsequently  results  in  the  diabetic 
phenotype  with  hypoadiponectinemia,  as  shown  to  be  true  for  some  adiponectin  mutants  [17]. 
Therefore, there is a need to be able to produce appropriately functional adiponectin in high quantities 
for pharmaceutical purposes, using cheap and convenient expression systems. 
It  is  a general  fact  that quantity  and quality of the recombinant  protein as  well as  the cost  of 
production  are  important  considerations  in  producing  pharmaceutical  therapies.  The  recombinant 
proteins which are produced by different host cells vary in protein characteristic such as effective 
translation due to codon specificity, post-translational modifications, as well as the size of the resulting 
protein  which  is  dependent  on  the  degree  of  glycosylation  [8].  For  instance,  certain  recombinant 
proteins expressed in E. coli required extra processing steps for denaturation and refolding, in order to 
obtain biologically active forms [18]. Furthermore, recombinant proteins which are produced inside or 
outside host cells differ in the extent of accumulation in inclusion bodies [18]. In previous studies, 
recombinant globular domain of human adiponectin produce by P. pastoris was biologically active [12]. 
However, it was also reported that the full length protein showed higher activity than the shorter form 
(globular domain) [19]. Globular domain adiponectin is also limited in its ability to induce cellular 
response, as it had been shown to only affect one of two types of adiponectin receptors [20]. In view of 
that, we chose P. pastoris as a cheap alternative expression system to extracellularly produce full 
length adiponectin, which are more effective biomolecules, without the need for refolding treatments 
or additional steps of purification. Adiponectin protein produced by E. coli showed good solubility, but Int. J. Mol. Sci. 2012, 13                         
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the  level  of  post  translation  modification  was  lower  than  that  of  P.  pastoris.  The  MBP  tag  was 
important in facilitating the production of soluble protein by E. coli. However, there would then be the 
requirement  of  additional  purification  steps  to  remove  MBP.  This  is  definitely  disadvantageous 
compared to one step purification in the case of expression in P. pastoris.   
In this study, two important factors facilitated high quantity production of ADP by P. pastoris. 
Firstly,  the  expression  of  ADP  was  driven  by  the  strong  and  tightly  regulated  AOX1  promoter. 
Secondly, a time-course study of adiponectin expression enabled us to determine the specific time of 
high expression of recombinant protein and low proteolytic activity. The culture at sixty hours after 
methanol induction yielded 0.111 mg/mL, and this is a reasonably good quantity compared with that 
produced by E. coli (0.1 mg/mL [11], 0.04–0.08 mg/mL [13]), 0.01 mg/mL by baculovirus [13] and 
0.05 mg/mL globular adiponectin expressed by P. pastoris [12]. The SDS-PAGE and western blotting 
analysis established that the approximated size of human adiponectin protein obtained in this study 
was similar to those previously reported [11,17]. 
Consistent  with  previous  findings  [19,21]
 ADP  was  effective  in  lowering  blood  glucose  and 
triglycerides. ADP as full length proteins has the ability to effectively influence both AdipoR1 and 
AdipoR2 receptors, which stimulate glucose uptake and fatty acids oxidation [22,23]. Likewise, ADP 
has  also  been  shown  to  be  beneficial  on  blood  lipid  profile  through  decreasing  triglycerides  and 
increasing  HDL.  As  such,  our  findings  and  results  from  several  other  studies  corroborate  the 
suggestion that ADP potentially has anti-atherogenic properties [24–26].   
4. Experimental Section 
4.1. Culture Media 
Escherichia coli strain JM109 and TB1 were cultured in standard LB broth and selective LB-agar. 
The selective LB-agar medium contains 2% agar, 0.5 mM isopropylthiogalactoside (IPTG), 80 µg/mL 
of  5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside  (X-Gal)  and  100  µg/mL  ampicillin.  E.  coli 
strain  TOP10  was  cultured  in  low  salt  LB  medium  (LSLB)  and  LSLB-Agar  with  zeocin™  (salt 
concentration < 90 mM and pH 7.5 for zeocin to be active). LSLB medium contains 1% peptone, 0.05% 
NaCl, 0.5% yeast extract and 1.5% agar with 25 g/mL Zeocin™ for solid medium. 
Escherichia coli expression strain TB1 were cultured in LB rich medium containing 100 μg/mL 
ampicillin, 1% peptone, 0.5% yeast extract, 0.5% NaCl and 0.2% dextrose. Whereas, P. pastoris were 
cultured in YPD broth, containing 2% peptone, 1% yeast extract, 2% dextrose and 100 mg/L Zeocin™ 
YPDS-agar was made by including 2% agar and 18% sorbitol. For gene expression purposes, the 
BMMY and BMGY media was used. These buffered complex media contained 2% peptone, 1% yeast 
extract, 4 ×  10
−5 % biotin, 1.34% yeast nitrogen base, 0.1 M potassium phosphate buffer, pH 6.0 and 1% 
glycerol for BMGY growth medium, or 1% methanol for BMMY induction medium.   
 
4.2. Gene Construction and Cloning 
Adiponectin  gene  reference  sequence  was  obtained  from  GenBank  under the reference number 
NC_000003.11. Exon 2 and exon 3 of the ADP fragment was amplified individually by polymerase 
chain reaction (PCR). The PCR conditions through 32 cycles were 95 °C  for 45 s as denaturing step, Int. J. Mol. Sci. 2012, 13                         
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60 °C  for 45 s as an annealing step and 72 °C  for 1 min as an elongation step. The two fragments were 
then joined by overlap-extension PCR. The reaction conditions of an overlap-extension PCR through 
10 cycles were denaturing step at 95 °C  for 45 s, annealing step at 60 °C  for 45 s and elongating step at 
72 °C  for 1 min. The pMAL™-p4 vector (New England Biolabs, UK) was used to produce ADP in   
E. coli periplasm. This vector was digested with Xmn I and Hind III restriction enzymes (Promega, 
USA). At the same time, ADP fragment which prepared to express by E. coli was digested with Hind 
III restriction enzyme. The ligation mixture was prepared by adding digested vector and digested ADP 
fragment with DNA ligase and its suitable ligation buffer (New England Biolabs, UK).   
Adiponectin fragment was cloned in pGEM
®-T cloning vector (Promega, USA). After sequence 
verification, the recombinant plasmid was double digested with EcoRI and NotI restriction enzymes to 
generate fragments with cohesive termini. Digested fragments were purified using the QIAquick Gel 
Extraction kit (Qiagen, USA), as described in the manufacturer’s protocol. To clone in P. pastoris, 
ADP fragment were then ligated to the pPICZαA plasmid which had been digested with EcoRI and 
NotI,  followed  by  phenol-chloroform  extraction  and  ethanol  precipitation.  Following  sequence 
verification, the pPICZαA-ADP recombinant plasmid was linearized with SacI and transformed into 
competent X-33 P. pastoris cells using the EasyComp™ (Invitrogen, Netherlands) procedure.   
4.3. Expression in E. coli 
Single colony of cells containing fusion plasmid was used to inoculate 10 mL of LB broth and 
grown overnight  at  37 °C .  An overnight  culture was  used to  inoculate one litre of an expression 
medium. The subculture was grown at 37 ° C with good aeration (250 rpm shaking) until OD600 was 
approximately 0.5. An aliquot sample of 1 mL was taken as non-induced cells and centrifuged for   
2 min. Then, cell pellet was resuspended in 50 µL of 1X SDS-PAGE sample buffer and frozen at 
−20 ° C. For induction, IPTG was added to the remaining culture to a final concentration of 0.3 mM 
and the culture was incubated at 37 ° C and 250 rpm shaking for 4 h. At each hour after induction a 
sample of 1 mL was taken and prepared for SDS-PAGE analysis.   
4.4. Expression and Optimization of Adiponectin Production by P. pastoris   
The recombinant X-33 single colony was inoculated in BMGY medium and grown at 30 ° C until 
OD600 was 2–6. The cell pellet was resuspended in BMMY media (or BGMY medium for control 
culture) at OD600 = 1, and grown at 30 ° C with shaking at 220 rpm. Methanol induction was carried out 
at 12 h intervals to a final concentration 0.5%, and harvesting was carried out at 12, 24, 36, 48, 60, 72, 
84 and 96 h after induction. Glycerol was added to the BMGY medium as a substitute for methanol. 
Supernatants  were  collected  from  harvested  cultures  and  secreted  proteins  were  analysed  by   
SDS-PAGE and western blot using anti-ADP antibody. In another experiment, five tubes containing 
10 mL YPD medium were inoculated with single recombinant X-33 colony and incubated for 16–18 h 
until OD600 reached 2 to 6. For growth phase culture, the harvested cells were transferred to five   
250 mL flasks containing 50 mL  BMGY media and cultured as previously described until OD600 
reached 2 to 6. Next, the harvested cells were resuspended in five 1 L flasks containing 200 mL 
BMMY media, and cultured until OD600 = 1. For induction phase, 100% methanol was added to a final 
concentration  of  0.5%  every  12  h  for  60  h  at  30  ° C  in  a  shaking  incubator  (250–300  rpm).  To Int. J. Mol. Sci. 2012, 13                         
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precipitate the secreted P-ADP, three volumes of acetone were added to the collected supernatants 
followed by incubation at −20 ° C overnight. The dissolved protein was resuspended with PBS buffer, 
subsequently purified by affinity chromatography and quantified using the Bradford method.   
4.5. Protein Purification 
4.5.1. E-ADP Purification by Amylose Resin Column 
The amylose resin was poured into a disposable polypropylene column of 25 mL volume (BioRad 
Econo-Pac™, U.S.A.). The bed volume was 5 mL and the column volume was 20 mL. The column 
was washed with 8 column volume of column buffer (20 mM Tris-HCl, 200 mM NaCl and 1 mM 
EDTA). Then, the crude extract was loaded into the column at a flow rate about 1  mL/min. The 
column  was  turned  off  for  15  min  to  enable  optimal  binding  between  the  fusion  protein  and  the 
amylose resin. Later, the column was washed with 12 column volume of column buffer. In order to 
elute the bound protein, one column volume of elution buffer (column buffer with 10 mM maltose) 
was added and the fractions (3 mL) were collected and kept at −80 ° C. 
4.5.2. Cleavage, Denaturing and Re-Purification of E-ADP 
First, a pilot experiment was carried out using small portion of protein sample to optimize the 
suitable time for Factor Xa ( Biolabs, UK) cleavage. Factor Xa final concentration of 1% was added to 
the  protein  sample,  the  positive  control  was  a  protein  sample  before  purification  (crude  protein) 
incubated with same concentration of Factor Xa. All samples were incubated for 2, 4 and 8 h. From 
each  reaction  5  μL  were  added  to  5  μL  of  2×   SDS-PAGE  sample  buffers  and  saved  at  4  ° C.   
SDS-PAGE was applied to determine the suitable time for cleavage. Then, the pilot experiment was 
scaled up for the portion of the fusion protein to be cleaved. Guanidine hydrochloride was added to the 
sample to a final concentration of 6 M. Later, the sample was dialysed against 100 sample volumes 
column buffer (20 mM Tris-HCl, 200 mM NaCl and 1 mM EDTA) three times for 2 h each. In order to 
remove the rest of maltose binding protein, the fusion protein cleavage mixture was loaded onto the 
hydroxyapatite  column  (BioRad  Econo-Pac™,  U.S.A.).  The  column  was  washed  with  80  mL  of   
20 mM sodium phosphate, 200 mM NaCl (pH 7.2). The protein mixture was eluted with 0.5 M Na 
phosphate (pH 7.2). The collected fractions were loaded onto amylose column and the flow through 
was collected that should be free of maltose binding protein (MBP).   
4.5.3. P-ADP Purification by Nickel Column 
Protein samples were purified by His GraviTrap™ Flow (Amersham Biosciences, USA) column 
containing precharged Ni Sepharose™ 6 Fast. The column was normalized with 8 mL of phosphate 
buffer (20 mM sodium phosphate buffer and 500 mM NaCl, pH 7.4). The sample (4 mL) was loaded 
into  the  column  and  the  column  was  washed  with  10  mL  of  binding  buffer  (phosphate  buffer 
containing 20 mM imidazole, pH 7.4). The recombinant protein was eluted with 4 mL of elution buffer 
(phosphate buffer containing 200 mM imidazole, pH 7.4).   
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4.6. SDS-PAGE and Western Immunoblotting 
Purified  P-ADP  and  E-ADP  proteins  were  separated  by  SDS-PAGE  in  denaturing  and  non-
denaturing (with and without heat and reducing agents) conditions. The proteins were then transferred 
onto polyvinylidene fluoride membrane as described elsewhere [17]. In brief, protein samples were 
loaded into 12% gels SDS-PAGE, and then transferred to a nitrocellulose membrane (1 h, 100 V). 
Following transfer, the membrane was blocked in Tris Buffered Saline with Tween-20 containing   
50 g/L skimmed milk for 2 h, and then incubated with adiponectin monoclonal antibody (abcam, UK) 
for 2 h at room temperature. The strips were washed three times with Tris Buffered Saline (15 min 
each time) and then incubated with mouse anti-IGg antibody conjugated with alkaline phosphatase 
(Sigma, USA) for 2 h, washed again with Tris Buffered Saline as described previously, and finally 
developed with Western Blue
® stabilized substrate (Promega, USA). 
4.7. Effect of Recombinant Adiponectin on Blood Glucose and Lipids 
Female ICR mice were used to compare the biological activity of ADP expressed in P. pastoris and 
E. coli. Animals were obtained from the Animal House, Faculty of Medicine, University of Malaya in 
Kuala  Lumpur  (Ethics  No.  PM  07/05/2010  MAA  (a)  (R).  Following  overnight  fasting,  animals   
(3 groups, n = 6 each) were gavaged with high fat-sucrose diet. Immediately after feeding, the first 
group  was  injected  with  0.9  mg/kg  of  bodyweight  P-ADP.  The  second  group  was  injected  with   
0.9 mg/kg of bodyweight E-ADP and the final group was injected with 0.3 mL saline for experiment 
control. After one hour of the first injection (or one hour after feeding) a second dose of treatment was 
given  to  all  mice  (the  total  amount  of  P-ADP  and  E-ADP  being  administered  for  each  mouse  = 
1.8 mg/kg bodyweight). Blood glucose was measured with a glucometer at one hour intervals for four 
hours.  In  addition,  blood  concentration  of  triglyceride  (TG),  total  cholesterol  (CHOL)  (Siemens, 
U.S.A.), low density lipoprotein (LDL) and high density lipoprotein (HDL) (Dade Behring, U.S.A.) 
were also measured at the end of the fourth hour of the experiment using available commercial kits.   
4.8. Statistical Analysis 
Values are expressed as means ±  S.E.M. The mean value comparisons between two groups were 
performed using the Student t test. Significant differences were considered at p < 0.05. 
5. Conclusions 
It is interesting to note that the P. pastoris expression system was able to produce higher quantity 
with simple purification and higher bioactivity of ADP compared to the expression by E. coli. All 
these  factors  together  make  P.  pastoris  the  favourable  expression  system  to  produce  recombinant 
human adiponectin for treatment of type II diabetes and cardiovascular diseases. 
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